Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00323011 · ClinicalTrials.gov registry record · Phase 2
FOLFIRI + Bevacizumab With or Without Dalteparin in First Line Treatment of Advanced Colorectal Cancer
A Phase 2 study, sponsored by University of Southern California.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT00323011 is a Phase 2 study that was terminated before completion, run by University of Southern California. The registered enrollment target is 5 participants.
The verdict
NCT00323011, a Phase 2 study, was terminated before completion, sponsored by University of Southern California.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
This study is for people with colorectal cancer, who have tumors that cannot be completely removed by surgery. Blood clots are a problem in patients with cancer. Blood clots are also a problem in patients receiving cancer drugs. Studies have shown that up to 17% of patients receiving cancer drugs experienced blood-clotting problems. One purpose of this study is to find if the drug combination of irinotecan, 5-fluorouracil (5-FU), bevacizumab and leucovorin (LV) affect blood-clotting factors. A second purpose of this study is to find out what effects the drug dalteparin has on clotting factors in the blood in patients receiving the drug combination of irinotecan, 5-FU, bevacizumab and LV. It is hoped that adding dalteparin to chemotherapy may benefit patients with colorectal cancer by preventing blood clots
Interventions
- DRUG Fragmin, 5-Fluorouracil, Folinic Acid, irinotecan, bevacizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2006-05 |
| Est. Completion | 2007-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00323011
The ClinicalTrials.gov registry entry for NCT00323011 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Fragmin, 5-Fluorouracil, Folinic Acid, irinotecan, bevacizumab is the first listed.
NCT00323011 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00323011 about?
NCT00323011 is a clinical study titled "FOLFIRI + Bevacizumab With or Without Dalteparin in First Line Treatment of Advanced Colorectal Cancer". This study is for people with colorectal cancer, who have tumors that cannot be completely removed by surgery. Blood clots are a problem in patients with cancer. Blood clots are also a problem in patients receiving cancer drugs. Studies have shown that up to 17% of patients receiving cancer drugs ex...
What is the current status of trial NCT00323011?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2006-05. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00323011?
The interventions under investigation include: Fragmin, 5-Fluorouracil, Folinic Acid, irinotecan, bevacizumab (DRUG).
Who is sponsoring clinical trial NCT00323011?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.